Want to see HK:9969 full AI Analyst Report?
Top Page
InnoCare Pharma Ltd.
(9969)
Select Model
Select Model
Rating:65Neutral
Price Target:
HK$12.50
▲(6.38% Upside)
Action:Downgraded
Date:10/29/26
The score is supported primarily by improving fundamentals and upbeat earnings-call guidance (sharp profitability turnaround, strong growth, solid liquidity and stated >35% drug-sales growth target). Offsetting this, the technical setup is weak with the stock trading below key moving averages and bearish MACD, while valuation is only moderately supportive (P/E ~19 and no dividend).
Positive Factors
Revenue and Profitability Inflection
The sharp revenue increase alongside a substantial swing into profit indicates meaningful commercial traction and operating leverage. If sustained through broader product adoption, this inflection can strengthen internal funding capacity and establish a more durable earnings base.
Negative Factors
Orelabrutinib Revenue Concentration
Heavy reliance on orelabrutinib concentrates near-term commercial performance in one product, increasing sensitivity to its growth, market access, and competitive position. Smaller contributions from other medicines mean diversification may take time to materially reduce this exposure.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue and Profitability Inflection
The sharp revenue increase alongside a substantial swing into profit indicates meaningful commercial traction and operating leverage. If sustained through broader product adoption, this inflection can strengthen internal funding capacity and establish a more durable earnings base.
Read all positive factors
InnoCare Pharma Ltd. (9969) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$17.44B
Dividend YieldN/A
Average Volume (3M)7.37M
Price to Earnings (P/E)12.9
Beta (1Y)1.20
Revenue Growth146.27%
EPS GrowthN/A
CountryHK
Employees1,388
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.77
Shares Outstanding1,496,284,200
10 Day Avg. Volume6,041,538
30 Day Avg. Volume7,371,307
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)2.52
Price to Sales (P/S)8.47
P/FCF Ratio148.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$19.07Price Target Upside62.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)0.2
Revenue Forecast (FY)HK$2.57B
InnoCare Pharma Ltd. Business Overview & Revenue Model
Company Description
InnoCare Pharma Limited, a biopharmaceutical enterprise, specializes in the discovery, development, and commercialization of therapeutic agents for oncological and autoimmune disorders. Its lead product, Orelabrutinib, a BTK inhibitor, addresses a...
How the Company Makes Money
InnoCare Pharma generates revenue primarily by commercializing approved medicines and selling them through pharmaceutical distribution channels to hospitals, clinics, and pharmacies, where applicable. A second major source of income is collaborati...
InnoCare Pharma Ltd. Earnings Call Summary
Earnings Call Date:Aug 24, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Apr 01, 2027
Earnings Call Sentiment Positive
The call presents a strongly positive commercial and financial picture in H1 2026: double-digit topline growth (55.5% YoY), a return to profitability (RMB 240 million net profit), strong cash (~RMB 8.4 billion) and positive operating cash flow. R&D investment is ongoing with multiple regulatory approvals/submissions, several Phase III successes, and broad pipeline progress (notably mesutoclax and ADC programs). Key risks are timing and execution of large Phase III programs, dependence on orelabrutinib for near-term revenue, the early-stage nature of many solid tumor programs, BD deal timing uncertainty, and safety/enrollment risks in some autoimmune programs. Overall, the highlights (robust growth, profitability, cash, approvals, and positive late‑stage data) outweigh the lowlights (timing, execution and competitive risks).Positive Updates
Strong Revenue Growth
Total revenue of RMB 1.137 billion in H1 2026, up 55.5% year-over-year.
Negative Updates
Revenue Concentration in Orelabrutinib
Management noted orelabrutinib contributed the majority of value growth (>30% growth for orelabrutinib) while tafasitamab and zurletrectinib, though showing high growth rates off a low base, remain small absolute contributors and zurletrectinib is not yet on NRDL.
Read all updates
Q2-2026 Updates
Positive
Negative
Strong Revenue Growth
Total revenue of RMB 1.137 billion in H1 2026, up 55.5% year-over-year.
Read all positive updates
Company Guidance
Management reiterated confidence in 2026 financial and operational targets: full‑year drug sales growth above 35% (building on H1 drug sales of RMB 918m, +43.2% YoY) and strong topline momentum after H1 total revenue of RMB 1.137bn (+55.5% YoY); H1 net profit was RMB 240m (vs a RMB 36m loss a year ago) with diluted EPS of RMB 0.14 and management expects full‑year profitability with EPS above the H1 level. Liquidity and investment metrics were highlighted—cash and related accounts of ~RMB 8.4bn (~$1.2bn) as of June 30, positive operating cash flow in H1, and R&D spend of RMB 497m (up 10.5% YoY)—and the company guided to multiple near‑term clinical and regulatory catalysts (e.g., first‑line CLL/SLL Phase III fixed‑duration readout H1 2027, anticipated ITP NDA approval by H1 2027, Phase I completions for ICP‑538 and ICP‑054 by year‑end, and a US IND for ICP‑B381 expected in September) to drive continued commercial expansion.InnoCare Pharma Ltd. Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
72
Positive
Cash Flow
61
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.33B | 2.30B | 1.01B | 738.54M | 625.40M | 1.04B |
| Gross Profit | 3.04B | 2.01B | 871.01M | 610.10M | 482.01M | 977.37M |
| EBITDA | 1.27B | 555.89M | -442.92M | -516.55M | -808.28M | 16.23M |
| Net Income | 1.35B | 625.84M | -440.63M | -631.26M | -886.59M | -64.55M |
Balance Sheet | ||||||
| Total Assets | 11.48B | 10.83B | 9.41B | 9.92B | 10.32B | 7.40B |
| Cash, Cash Equivalents and Short-Term Investments | 6.49B | 7.34B | 6.22B | 8.22B | 9.01B | 6.25B |
| Total Debt | 2.13B | 1.61B | 1.27B | 1.35B | 1.54B | 1.27B |
| Total Liabilities | 3.27B | 3.07B | 2.66B | 2.74B | 2.68B | 1.74B |
| Stockholders Equity | 8.20B | 7.73B | 6.73B | 7.15B | 7.60B | 5.60B |
Cash Flow | ||||||
| Free Cash Flow | 327.66M | 130.80M | -443.78M | -926.00M | -935.88M | -11.00K |
| Operating Cash Flow | 459.76M | 199.15M | -365.55M | -671.34M | -565.55M | 167.06M |
| Investing Cash Flow | -1.20B | -358.03M | 1.11B | 666.91M | -1.73B | -1.73B |
| Financing Cash Flow | 102.83M | -32.84M | -285.60M | 1.31M | 3.09B | 2.54B |
InnoCare Pharma Ltd. Technical Analysis
Negative
11.75
Price Trends
13.81
Negative
13.42
Negative
13.09
Negative
Market Momentum
-0.69
Positive
36.08
Neutral
18.47
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9969, the sentiment is Negative. The current price of 11.75 is below the 20-day moving average (MA) of 12.55, below the 50-day MA of 13.81, and below the 200-day MA of 13.09, indicating a bearish trend. The MACD of -0.69 indicates Positive momentum. The RSI at 36.08 is Neutral, neither overbought nor oversold. The STOCH value of 18.47 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:9969.
InnoCare Pharma Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | HK$17.44B | 12.89 | 17.47% | ― | 146.27% | ― | |
61 Neutral | HK$18.66B | 41.95 | 15.94% | ― | 48.04% | 166.72% | |
52 Neutral | HK$22.08B | -12.93 | -27.40% | ― | 5.38% | 16.86% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | HK$10.50B | -6.15 | -153.78% | ― | 70.26% | -12.79% | |
48 Neutral | HK$6.51B | -57.92 | -9.45% | ― | 68.12% | 81.84% | |
41 Neutral | HK$7.45B | -14.89 | -43.54% | ― | 116.67% | -0.42% |
* Healthcare Sector Average
HK:9969
InnoCare Pharma Ltd.
11.67
-2.58
-18.11%
HK:9688
Zai Lab Ltd
17.68
-2.42
-12.04%
HK:2171
CARsgen Therapeutics Holdings Ltd.
10.95
-5.53
-33.56%
HK:2315
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
42.00
14.00
50.00%
HK:2616
CStone Pharmaceuticals
4.74
-1.52
-24.36%
HK:6855
Ascentage Pharma Group International
28.22
-38.28
-57.56%
InnoCare Pharma Ltd. Corporate Events
InnoCare Pharma Issues Unaudited Q3 2026 Report Under PRC Accounting Rules
Oct 26, 2026
InnoCare Pharma Limited has issued its unaudited third-quarter 2026 report, prepared under People’s Republic of China accounting principles to meet STAR Market requirements on the Shanghai Stock Exchange. The company has provided an English ...
InnoCare Pharma Sets Board Meeting to Approve Q3 2026 Results
Oct 12, 2026
InnoCare Pharma Limited has scheduled a board meeting for 26 October 2026 to review and approve its unaudited third‑quarter results for the nine months ended 30 September 2026. The approval and subsequent publication of these results will pr...
InnoCare Pharma Strikes Multibillion-Dollar Drug Discovery Pact With Eli Lilly
Sep 24, 2026
InnoCare Pharma has entered into a strategic research collaboration and license agreement with global pharmaceutical major Eli Lilly and Company to co-develop new medicines targeting up to five disease-related pathways. InnoCare will use its propr...
InnoCare Pharma Swings to Profit on Surging Drug Sales and New Launches
Aug 24, 2026
InnoCare Pharma reported a sharp increase in interim revenue, with total income rising 55.5% to RMB1,137.1 million in the six months ended 30 June 2026, driven by 43.2% growth in drug sales to RMB918.1 million. The performance was supported by sus...
InnoCare Pharma Sets Board Meeting to Approve 2026 Interim Results
Aug 11, 2026
InnoCare Pharma Limited has scheduled a board meeting for 24 August 2026 to review and approve the interim results for the six months ended 30 June 2026. The board will also approve the publication of these results, a routine but important step th...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.